Hologic — Debt Investor Presentation (March 2013)
20 slides from Hologic's debt investor presentation, Mar 5, 2013
Slide 1: Presentation to Lenders
Exhibit 99.1 Presentation to Lenders March 5, 2013
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information included herei
Slide 3: Transaction Overview
Transaction Overview Hologic, Inc. ("Hologic" or "the Company") (NASDAQ: HOLX) is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women Hologic has continued to demonstrate stro
Slide 4: Pro Forma Capitalization
Pro Forma Capitalization Amounts as of December 29, 2012 ($ in millions) Current CCR: B1 / BB Amount Leverage Coupon Floor Maturity Put Date Cash $718.5 Revolver ($300) - L+300 - Aug-17 Term Loan A 979.7 L+300 - Aug-17 Term Loan B 1,482.0 L+350 1.00% Aug-19 Total Secured Debt 2,461.7 2.5 x Senior Un
Slide 5: Total Revenues by Business Segment
Total Revenues by Business Segment Consolidated Non-GAAP Adjusted Q1’13 Revenues of $644.6M (unaudited) Total Diagnostics $319.2M* 49% Capital $120.5M Breast Health $220.8M 34% Service $96.2M Consumables $427.9 GYN Surgical $80.9M 13% Skeletal Health $23.7M 4% Consumables/Service ~81% Capital Equipm
Slide 6: Business and Product Update
Business and Product Update PANTHER launch progressing smoothly with positive early traction FDA approval of APTIMA 16 18/45 Genotype Assay for use on TIGRIS announced on October 16, 2012 Definitive agreement announced on January 3, 2013 to sell the Company’s LIFECODES business to Immucor, Inc. for
Slide 7: Advancing Breast Cancer Screening
Advancing Breast Cancer Screening 7
Slide 8: 3D Dimensions Tomosynthesis
3D Dimensions Tomosynthesis Superior Next-Generation Digital Mammography Improved Tissue Visualization and Detection Superiority over 2D Digital Mammography Lower Recall Rates Tomosynthesis…uptake ahead of expectations • U.S. installed base of ~ 11,000 digital systems – potential for conversion to T
Slide 9: Tomosynthesis Clinical Efficacy
Tomosynthesis Clinical Efficacy Oslo Tomosynthesis Screening Trial Compared to 2D, U.S. sites report a reported breast cancer screening significant reduction in recalls with with Hologic’s Tomosynthesis significantly Hologic’s tomosynthesis 2-3 1 improves cancer detection 40% 27% in invasive overall
Slide 10: Q1 2013 Financial Results
Q1 2013 Financial Results Consolidated non-GAAP adjusted revenues were $644.6 million, a year-over-year increase of $171.9 million, or 36.4%, and at the high-end of our guidance range of $640 to $645 million. The Company's GAAP revenues for the same period were $631.4 million 1 Non-GAAP adjusted EPS
Slide 11: Q1 FY 2013 Overview
Q1 FY 2013 Overview Quarter Ended December 29, 2012 (unaudited) Key Performance Metrics Q1 FY 2013 GAAP revenues of $631.4 million and non-GAAP Revenues revenues of $644.6 million • Non-GAAP revenues up $171.9 million, or 36.4%, vs. Q1’12 1 • Non-GAAP revenues up $44.5 million, or 7.4%, vs. Q4’12 GA
Slide 12: Fiscal 2013 Guidance
Fiscal 2013 Guidance Quarter Ending March 30, 2013 and Year Ending September 28, 2013 Non-GAAP* $s in millions FY 2013 Q2 2013 (except EPS) (Guidance)* (Guidance) * Revenues $2,610 – $2,640 $635 – $640 Gross Margins 63.0% 62.5% – 63.0% Operating Expenses $785 – $810 $205 – $210 Interest Expense $220
Slide 13: Balance Sheet & Debt Paydown Road Map
Balance Sheet & Debt Paydown Road Map Focus on de-leveraging — Total debt obligations of $5.0 billion, including $3.5 billion borrowed for acquisition of Gen-Probe — Goal to reduce total debt to EBITDA from approximately 5.1x to 2.5x during the three-year period post-acquisition (down to 4.5x at the
Slide 14: Amendment Overview
Amendment Overview Hologic is seeking to reprice its Revolver and Term Loan A In addition, the amendment would make certain other changes in the Credit Agreement, including: — Allow the Company to purchase or repurchase its Convertible Notes during the eighteen months prior to their respective put d
Slide 15: Slide 15
Slide 16: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) In thousands, except earnings per share Continued on next page 16
Slide 17: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) In thousands, except earnings per share Three Months Ended Last Twelve Months December 29, 2012 December 24, 2011 September 29, 2012 December 29, 2012 OPERATING EXPENSES GAAP operating expenses $218,444 $182,611 $318,020 $916,553 Adjustments: Amortizati
Slide 18: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) In thousands, except tax rates Footnotes: 1 To primarily reflect a fair value adjustment recorded in purchase accounting relating to contingent revenue earned and received under the Novartis collaboration post acquisition, which was eliminated under pur
Slide 19: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures Hologic has presented the following non-GAAP financial measures in this presentation: adjusted revenues; adjusted gross margins; adjusted operating expenses; adjusted operating income; adjusted interest expense; adjusted pre-tax income; adjusted net income; adjuste
Slide 20: Financial Guidance
Financial Guidance The Company’s guidance includes its current operations, including revenues from its approved/cleared products and its recently acquired businesses. Hologic may not generate expected revenues and may incur expenses or charges, realize income or gains, or execute acquisitions or dis